Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Immutep S A S is active in the Biotechnology & Pharmaceuticals technology area. The company's portfolio currently features 4 pending office actions. These actions are distributed across 3 distinct art units, indicating that the company's biological innovations span several specialized groups within the patent office. This distribution suggests a relatively broad technical scope for the company's current filings in the pharmaceutical sector.
The prosecution involves 4 distinct examiners, meaning each of the 4 pending actions is being handled by a different individual. CHASE, CAROL ANN is identified as the busiest examiner for the company, with 1 pending office action. With 4 different examiners and 3 art units involved, the practitioner must manage multiple parallel prosecution tracks. This requires navigating the various examination styles and requirements of several individuals within the Biotechnology & Pharmaceuticals field simultaneously. Such a diverse prosecution environment necessitates a highly coordinated strategy to ensure consistency across all pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHASE, CAROL ANN | 1 | 42.6% | +84.7% |
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
| NICKOL, GARY B | 1 | 47.1% | +31.1% |
| GAO, ASHLEY HARTMAN | 1 | 56.7% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17607784 | ASSAYS | GAO, ASHLEY HARTMAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928048 | TREATMENT OF CANCER | DENT, ALANA HARRIS | 29d |
| 18570846 | TRIPLE COMBINATION THERAPY | CHASE, CAROL ANN | — |
| 17607828 | ANTI-LAG-3 BINDING MOLECULES | NICKOL, GARY B | — |
| 17607784 | ASSAYS | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1600 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570846 | TRIPLE COMBINATION THERAPY | CHASE, CAROL ANN | — | §102§103§112DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 17928048 | TREATMENT OF CANCER | DENT, ALANA HARRIS | 1643 | DP | Non-Final OA | 29d | Pending | Nov 28, 2022 |
| 17607828 | ANTI-LAG-3 BINDING MOLECULES | NICKOL, GARY B | 1600 | §112 | Final Rejection | — | Pending | Oct 29, 2021 |
| 17607784 | ASSAYS | GAO, ASHLEY HARTMAN | 1678 | §103§112 | Non-Final OA | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial